Spotlight: : Enabling IV, brain-wide AAV gene delivery through an FDA-informed, GMP-ready platform

• Development of human receptor–targeting capsids (TfR1 CapX) to enable efficient, translatable blood–brain barrier crossing and broad CNS gene delivery
• Preclinical data showing improved CNS biodistribution and compatibility with scalable AAV manufacturing processes
• Strategies for facilitating access to novel capsids through industry and academic collaborations